Dose-response meta-analysis of differences in means

BMC Medical Research Methodology

Volumn 16, Issue 1, 2016, Pages

  Crippa, Alessio ^a   Orsini, Nicola ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dose response; Mean differences; Meta analysis; Random effects

Indexed keywords

NEUROLEPTIC AGENT;

ALGORITHM; DOSE RESPONSE; HUMAN; MARKOV CHAIN; META ANALYSIS (TOPIC); NONLINEAR SYSTEM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALGORITHMS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; META-ANALYSIS AS TOPIC; NONLINEAR DYNAMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOCHASTIC PROCESSES;

EID: 84988419926     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/s12874-016-0189-0     Document Type: Article

References (39)

1. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005; 61(3):738-48. doi: 10.1111/j.1541-0420.2005.00344.x. Accessed 24 Feb 2015
2. Bretz F, Hsu J, Pinheiro J, Liu Y. Dose finding - a challenge in statistics. Biometrical Journal. Biometrische Zeitschrift. 2008; 50(4):480-504. doi: 10.1002/bimj.200810438.
3. Pinheiro JC, Bretz F, Branson M. Analysis of dose-response studies. modeling approaches. In: Dose Finding in Drug Development. New York City: Springer: 2006. p. 146-71.
4. Ting N. Dose finding in drug development. New York City: Springer; 2006.
5. Chevret S. Statistical methods for dose-finding experiments. New York City: Wiley; 2006.
6. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992; 135(11):1301-1309.
7. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 1993; 4(3):218-28.
8. Dumouchel W. Meta-analysis for dose-response models. Stat Med. 1995; 14(5-7):679-85.
9. Bagnardi V, Zambon A, Quatto P, Corrao G. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol. 2004; 159(11):1077-1086. doi: 10.1093/aje/kwh142. Accessed 25 Nov 2013
10. Liu Q, Cook NR, Bergström A, Hsieh CC. A two-stage hierarchical regression model for meta-analysis of epidemiologic nonlinear dose-response data. Comput Stat Data Anal. 2009; 53(12):4157-167.
11. Orsini N, Bellocco R, Greenland S, et al. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006; 6(1):40.
12. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012; 175(1):66-73.
13. Dominici F, Samet JM, Zeger SL. Combining evidence on air pollution and daily mortality from the 20 largest us cities: a hierarchical modelling strategy. J Royal Stat Soc Ser A (Stat Soc). 2000; 163(3):263-302.
14. Simmonds MC, Higginsa JP, Stewartb LA, Tierneyb JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005; 2(3):209-17.
15. Gasparrini A, Armstrong B, Kenward MG. Multivariate meta-analysis for non-linear and other multi-parameter associations. Stat Med. 2012; 31(29):3821-839. doi: 10.1002/sim.5471. Accessed 11 Dec 2013
16. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004; 24(2):192-208.
17. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981; 6(6):429-53.
18. Thomas N, Sweeney K, Somayaji V. Meta-analysis of clinical dose-response in a large drug development portfolio. Stat Biopharm Res. 2014; 6(4):302-17. doi: 10.1080/19466315.2014.924876. Accessed 11 Feb 2015
19. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ: British Medical Journal. 2000; 321(7273):1371-1376. Accessed 24 Mar 2015.
20. Macdougall J. Analysis of dose-response studies. emax model. In: Dose Finding in Drug Development. New York City: Springer: 2006. p. 127-45.
21. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8(5):551-61. doi: 10.1002/sim.4780080504. Accessed 30 Mar 2015
22. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010; 29(9):1037-1057. doi: 10.1002/sim.3841. Accessed 25 Nov 2013
23. Harrell F.E. Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988; 80(15):1198-1202.
24. Royston P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med. 2000; 19(14):1831-1847.
25. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31(29):3805-820.
26. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954; 10(1):101-29. doi: 10.2307/3001666. Accessed 09 Jan 2015
27. Ritz J, Demidenko E, Spiegelman D. Multivariate meta-analysis for data consortia, individual patient meta-analysis, and pooling projects. J Stat Plann Infer. 2008; 138(7):1919-1933.
28. Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD. The efficacy and safety of lower soses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectrums. 2006; 11(09):691-702. doi: 10.1017/S1092852900014784. Accessed 06 Feb 2015
29. McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007; 41(11):895-905. doi: 10.1016/j.jpsychires.2007.05.002.
30. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63(9):763-71.
31. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatr. 2003; 60(7):681-90. doi: 10.1001/archpsyc.60.7.681.
32. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration Database. PLoS Med. 2012;9(3). doi: 10.1371/journal.pmed.1001189. Accessed 30 Mar 2015.
33. Obermeier M, Schennach-Wolff R, Meyer S, Möller HJ, Riedel M, Krause D, Seemüller F. Is the panss used correctly? a systematic review. BMC psychiatry. 2011; 11(1):1.
34. Leucht S, Kissling W, Davis JM. The PANSS should be rescaled. Schizophrenia bulletin. 2010; 36:461-462.
35. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining response in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007; 32(9):1903-1910.
36. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005; 5(1):14.
37. Sauerbrei W, Royston P. A new strategy for meta-analysis of continuous covariates in observational studies. Stat Med. 2011; 30(28):3341-360.
38. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol. 1994; 140(3):290-6.
39. Crippa A, Orsini N. Multivariate dose-response meta-analysis: the dosresmeta r package. J Stat Softw. 2016. In Press.